Biologics outsourcing lifts CMO/CDMO biotechnology market toward $168.9B by 2032

Persistence Market Research says the global CMO/CDMO biotechnology market will grow from $74.0 billion in 2025 to $168.9 billion by 2032, powered by biologics outsourcing, advanced therapies and digital manufacturing. North America leads today, while Asia Pacific is expected to grow fastest. Why it matters: - The CMO/CDMO biotechnology market is set to nearly double by 2032 as drugmakers outsource more biologics development and manufacturing. - The shift supports faster commercialization, lower capital spending and more flexible production for pharmaceutical and biopharmaceutical companies. - Demand is rising for specialized capacity in biologics, cell and gene therapies and smart manufacturing systems. What happened: - Persistence Market Research updated its global CMO/CDMO biotechnology market analysis. - The market is estimated at $74.0 billion in 2025 and is projected to reach $168.9 billion by 2032. - The forecast implies a 12.5% compound annual growth rate. - The report points to increasing biologics outsourcing, advanced therapy development and digital transformation in biomanufacturing as the main growth drivers. - The report includes a sample download and customization request through the company’s sample report page and the customization page . The details: - Monoclonal antibodies are expected to account for nearly 45% of market share. - CDMOs are expanding bioreactor capacity, using single-use technologies and improving fill-finish operations to meet demand. - Cell and gene therapies are creating more work for CDMOs with viral vector manufacturing and advanced bioprocessing capabilities. - Standalone services currently hold about 60% share, supported by demand for analytical testing, process optimization, cell-line development and fill-finish work. - Integrated development and manufacturing services are expected to be the fastest-growing service segment through 2032. - Cell and gene therapies are projected to post the highest product-category growth, at about 15% CAGR. - North America accounts for about 42% of global revenue. - Asia Pacific is projected to be the fastest-growing region, with nearly 14% CAGR through 2032. - Europe is growing steadily on biosimilar production, advanced therapy development and regulatory harmonization. - Major market participants include Lonza, Thermo Fisher Scientific, Samsung Biologics, Boehringer Ingelheim and AGC Biologics. Between the lines: - The market is moving from basic outsourced production toward more integrated, tech-enabled manufacturing partnerships. - Biopharma companies appear to favor asset-light models that reduce upfront investment while preserving access to complex manufacturing skills. - Digital tools such as artificial intelligence, machine learning, Industrial IoT, predictive analytics and digital twins are becoming part of the manufacturing stack. - Smart manufacturing demand accelerated from 2024 to 2025 as companies pushed for more transparency, shorter timelines and tighter process control. - Real-time monitoring, cloud analytics, predictive maintenance and automated documentation are becoming standard in advanced facilities. - LOTTE BIOLOGICS announced a manufacturing partnership in 2025 with a U.S.-based biopharmaceutical company for a late-stage biologics program, including Phase III production support and possible commercial manufacturing through 2030 after regulatory approval. - The deal underscores South Korea’s growing role in the global biologics supply chain and the value of long-term CDMO contracts. What’s next: - Capacity expansion, digital manufacturing investments and advanced therapy capabilities are likely to stay central to competition. - Asia Pacific is positioned to gain share as China, India and South Korea add infrastructure and R&D spending. - Long-term manufacturing agreements should keep shaping the market as drugmakers seek scalable, reliable outsourcing partners. - The report says integrated outsourcing models will keep gaining traction as companies look to streamline development and regulatory submissions. The bottom line: - Biologics outsourcing is becoming a core growth engine for the CDMO industry, and the winners are likely to be providers with scale, digital tools and advanced therapy expertise.